Behavioral Interview (STAR)· Oct 22, 2026

"So what changes when that rule changes?" Preparing interview follow-ups with three stories from Issue #21

After you mention a news story, the next question is often about a concept. I took the three rule-change stories in Issue

Relevant roles: Regulatory affairsBDMarket access

In using industry news in interviews I wrote up a three-step answer: fact → interpretation → my role. While studying, I realised that even a good answer can be followed straight away by a concept question, such as "So does a CHMP opinion mean the drug is approved?"

All three stories in BIO:ON Insight Issue #21 were about rules changing. For each one I picked a likely follow-up question and built the skeleton of an answer from public sources. The questions come from the "questions to think about" at the end of Issue #21.

1. Regulatory affairs: "How does a CHMP positive opinion differ from EC approval?"

The story: On 15 October 2026, the European Medicines Agency's human medicines committee (CHMP) recommended an EU marketing authorisation for Lilly's once-daily GLP-1 pill Foundayo (orforglipron) [1][2].

Indications: type 2 diabetes and weight management.
Weight management: people lost about 5–11% of body weight over 72 weeks, against 2–2.5% on placebo [1][2].
Context: it would be the second oral GLP-1 for weight management in the EU, after Novo Nordisk's Wegovy pill [2].

Skeleton answer:

A CHMP opinion is a recommendation. The legally binding marketing authorisation comes from the European Commission (EC) [3].
The EC normally decides within 67 days of the opinion. Until then the drug isn't authorised in the EU [3].
Authorisation isn't launch. An EC authorisation covers the whole EU (plus Iceland, Liechtenstein and Norway), but each member state sets price and reimbursement separately [1][3].

The role that handles this every day: Prospects describes a regulatory affairs officer's work like this [4]:

preparing and submitting marketing authorisation applications
answering regulators' questions
coordinating timelines with R&D, clinical, quality and manufacturing teams

Knowing the order (CHMP, then the EC, then country-by-country reimbursement) helps explain why regulatory affairs keeps managing timelines after the authorisation itself.

2. BD: "What changes between acquiring and licensing a Chinese asset?"

The story: On 16 October 2026, China's Ministry of Commerce (MOFCOM) and Ministry of Science and Technology published a draft revision of the technology export catalogue [5][6].

Proposed prohibited items: cell and gene therapy (CGT) process platforms and siRNA drug process platforms with independent intellectual property [6][7].
Consultation: comments are open until 15 November [5]. It isn't a final rule yet.

Skeleton answer:

Acquisition: ownership of the company or platform moves abroad. According to a law firm's analysis, the draft is aimed at blocking exactly this kind of platform ownership transfer [7].
Licensing: ownership stays with the Chinese company, and only the rights to develop and sell a specific product move. The same analysis says ownership-retaining product licences are carved out of the prohibition [7].
What's uncertain: reports read the scope slightly differently. So I think the accurate answer adds that each deal needs checking until the final text is out [5][6][7].

The role that handles this every day: BD job postings describe the work in four stages [8]:

searching for in-licensing candidates
evaluating data, patents and regulatory pathways
due diligence
negotiating the deal

If the draft becomes final, I understand it as one more line on the due-diligence checklist for Chinese assets: "Does this deal transfer ownership?"

3. Market access: "If 340B discounts become rebates, how does gross-to-net change?"

The story: On 1 October, the US Health Resources and Services Administration (HRSA) approved 10 manufacturers and 21 drugs for its 340B rebate pilot, which is due to start on 1 January 2027 [9].

The hospitals' lawsuit: on 9 October, the American Hospital Association (AHA) and hospitals sued in federal court in Maine to block the pilot [10].
Drugmakers step in: AbbVie (with Pharmacyclics), BMS and Boehringer Ingelheim moved to intervene on 14 October, and PhRMA on 15 October [10][11].

Skeleton answer:

What gross-to-net means: the gap between a drug's list (gross) price and what the manufacturer actually keeps (net), after rebates, distribution fees, returns, hospital discounts, 340B price reductions and so on [12].
Discount vs rebate: today a 340B hospital buys the drug at the discounted price up front. Under a rebate model, the hospital pays a higher price first, then claims the difference back after the drug is dispensed to an eligible patient [13].
HRSA's stated aim: to stop the 340B discount overlapping with Medicaid rebates or Medicare negotiated prices (duplicate discounts) [13].
Why hospitals object: administrative burden, and cash tied up while they wait for rebates. The hospitals argue the pilot could cost them more than $1 billion a year [10][13].

The role that handles this every day: market access is described as "making sure as many patients as possible who could benefit can get the product", with pricing strategy and reimbursement at its core [14]. When the route a discount takes changes, as with 340B, the same list price can lead to a different net. That seems like something a market access candidate should be able to explain.

My own view: I don't think this question is about giving the right number. The key is to describe both sides: manufacturers lose fewer duplicate discounts, while hospitals have cash tied up.

How I practised

Treat the "questions to think about" at the end of each issue as follow-up questions, and write a 30-second answer first.
For every concept in the answer, find one line from an official source (EMA, HRSA and so on). This is where I caught the things I'd remembered wrongly.
Finish with one line on "which role deals with this every day?" It's good practice for linking an answer back to the role you're applying for.

For more practice, you can draw questions for the same role from the interview question bank.

What I've learned

All three headlines ended in "approved", "blocked" or "changed", but each story was actually at a stage before anything was final: an EC decision still pending, a draft open for comment, and a pilot being challenged in court. When you mention a regulatory story in an interview, adding one phrase on what stage it's at should make the answer sound much more precise.

1. Regulatory affairs: "How does a CHMP positive opinion differ from EC approval?"

2. BD: "What changes between acquiring and licensing a Chinese asset?"

3. Market access: "If 340B discounts become rebates, how does gross-to-net change?"

How I practised

What I've learned

Sources